Biodexa Pharmaceuticals (BDRX) Cash from Investing Activities (2013 - 2022)

Biodexa Pharmaceuticals has reported Cash from Investing Activities for 8 years, with the latest figure at -$19939.8 in Q4 2022.

• Quarterly Cash from Investing Activities rose 89.94% year-over-year to -$19939.8 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$443376.0 (up 29.56% YoY) and the FY2025 annual result came in at -$768691.5, changed 0.15% from the prior year.
• Cash from Investing Activities rose to -$19939.8 in Q4 2022 per BDRX's latest filing, from -$21024.3 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at -$19939.8 in Q4 2022 and troughed at -$1.3 million in Q4 2019.
• A 4-year average of -$274669.8 and a median of -$116199.7 in 2020 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2020 and 2021: Cash from Investing Activities soared 90.72% in 2020, then tumbled 84.32% in 2021.
• Over 4 years, Cash from Investing Activities stood at -$1.3 million in 2019, then surged by 90.72% to -$116199.7 in 2020, then sank by 70.53% to -$198157.6 in 2021, then surged by 89.94% to -$19939.8 in 2022.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$19939.8, -$21024.3, and -$198157.6 for Q4 2022, Q3 2022, and Q4 2021 respectively.